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Abstract
Background: The primary goal of breast-conserving surgery (BCS) is to completely excise the tumor and
achieve "adequate" or "negative" surgical resection margins while maintaining an acceptable level of postoperative
cosmetic outcome. Nevertheless, precise determination of the adequacy of BCS has long been debated. In this
regard, the aim of the current paper was to describe a standardized and reproducible methodology for
comprehensive and systematic assessment of surgical resection margins during BCS.
Methods: Retrospective analysis of 204 BCS procedures performed for invasive breast cancer from August 2003
to June 2007, in which patients underwent a standard BCS resection and systematic sampling of nine standardized
re-resection margins (superior, superior-medial, superior-lateral, medial, lateral, inferior, inferior-medial, inferior-
lateral, and deep-posterior). Multiple variables (including patient, tumor, specimen, and follow-up variables) were
evaluated.
Results: 6.4% (13/204) of patients had positive BCS specimen margins (defined as tumor at inked edge of BCS
specimen) and 4.4% (9/204) of patients had close margins (defined as tumor within 1 mm or less of inked edge
but not at inked edge of BCS specimen). 11.8% (24/204) of patients had at least one re-resection margin containing
additional disease, independent of the status of the BCS specimen margins. 7.1% (13/182) of patients with negative
BCS specimen margins (defined as no tumor cells seen within 1 mm or less of inked edge of BCS specimen) had
at least one re-resection margin containing additional disease. Thus, 54.2% (13/24) of patients with additional
disease in a re-resection margin would not have been recognized by a standard BCS procedure alone (P < 0.001).
The nine standardized resection margins represented only 26.8% of the volume of the BCS specimen and 32.6%
of the surface area of the BCS specimen.
Conclusion: Our methodology accurately assesses the adequacy of surgical resection margins for determination
of which individuals may need further resection to the affected breast in order to minimize the potential risk of
local recurrence while attempting to limit the volume of additional breast tissue excised, as well as to determine
which individuals are not realistically amendable to BCS and instead need a completion mastectomy to successfully
remove multifocal disease.
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Background
Breast-conserving surgery (BCS) followed by whole-breast
radiation therapy is a well-established standard of care for
the treatment of early-stage invasive breast cancer [1,2].
This has been shown to be essentially equivalent to mas-
tectomy with regards to local control and survival [3-8].
The primary goal of BCS is to completely excise the tumor
and achieve "adequate" or "negative" surgical resection
margins while maintaining an acceptable level of postop-
erative cosmetic outcome to the affected breast. Neverthe-
less, the precise determination of the adequacy of surgical
resection margins during BCS has long been debated [8-
17]. There have been two major questions that have been
central to this ongoing debate. First, what represents the
most appropriate definition of an "adequate" or "nega-
tive" surgical margin? Second, what is the most optimal
manner in which to assess the adequacy of the surgical
margins?
In this regard, the aim of the current paper was to describe
a standardized and reproducible methodology for the
comprehensive and systematic assessment of surgical
resection margins during BCS for invasive breast cancer.
This methodology attempts to limit the volume of addi-
tional breast tissue excised, yet it attempts to optimize the
determination of which individual patients may need fur-
ther tissue resection from the affected breast in order to
minimize the potential risk of local recurrence following
BCS.
Methods
This study protocol was approved by the Clinical Scien-
tific Review Committee (protocol number OSU 07016)
and by the Cancer Institutional Review Board (protocol
number 2007C0009) of the Arthur G. James Cancer Hos-
pital and Richard J. Solove Research Institute and Com-
prehensive Cancer Center of The Ohio State University.
All patients who underwent BCS for invasive breast cancer
were identified from a prospectively maintained operative
log of a single surgeon (SPP). Prior to August 2003, each
BCS procedure was done without the use of any standard-
ized methodology of assessing the surrounding perimeter
of the resultant BCS resection bed cavity. Starting in
August 2003, such a standardized and reproducible meth-
odology of assessment of surgical resection margins (for
both the BCS specimen itself and for the surrounding
perimeter of the resultant BCS resection bed cavity) dur-
ing BCS for invasive breast cancer was initiated by the sur-
geon (SPP). Therefore, all BCS cases from August 2003 to
June 2007 for invasive breast cancer were selected for the
current analysis. All BCS procedures performed for a diag-
nosis of ductal carcinoma in situ (DCIS) alone were not
included in the current analysis. BCS was not offered or
undertaken in patients that had any additional suspicious
lesions within the affected breast that were demonstrated
on preoperative mammogram, ultrasound, or magnetic
resonance imaging (MRI) unless those additional suspi-
cious lesions were first biopsied and proven not to repre-
sent additional foci of breast malignancy within the
affected breast. In those cases in which those additional
suspicious lesions were first biopsied and proven to repre-
sent additional foci of breast malignancy within the
affected breast or in those cases in which patients elected
not to have those additional suspicious lesions biopsied
within the affected breast, only mastectomy was offered to
those patients.
All cases were performed in the operating room at the
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute of The Ohio State University. These pro-
cedures were generally done under general anesthesia
along with concomitant evaluation of the axillary lymph
nodes with sentinel lymph node biopsy and axillary
lymph node dissection, when indicated. For all non-pal-
pable or questionably-palpable tumors, pre-resection
tumor localization was accomplished by either mammo-
graphic guidance or sonographic guidance.
A standardized rationale was consistently utilized for the
determination of the extent of tissue resection during each
BCS procedure. For each BCS procedure, an overlying skin
ellipse was incised with a #10 surgical blade. Division of
the breast parenchymal was performed with the coagula-
tion mode of the electrocautery (Force 4B Electrosurgical
Generator, Valleylab™, Boulder, Colorado). In all cases,
wide local excision of breast parenchyma around the
tumor was undertaken, along with en bloc removal of an
ellipse of overlying skin (Figure 1). As is a standard of
practice for BCS, all attempts were made by the operating
surgeon to remove the tumor with what grossly appeared
at the time of surgery to be at least a 1 cm rim of surround-
ing normal-appearing breast tissue around all aspects of
the tumor. Additionally, concomitant excision of underly-
ing breast parenchyma all the way down to and including
the pectoralis major muscle fascia was performed for all
tumors located within the posterior two-thirds of the
breast parenchyma and was performed only selectively for
tumors located within the anterior one-third of the breast
parenchyma. Conversely, such a concomitant excision of
breast parenchyma all the way down to and including the
pectoralis major muscle fascia was generally excluded for
tumors located very superficially within the breast paren-
chyma in a location just under the skin of the breast.
Lastly, for very deeply placed tumors abutting or involving
the underlying pectoralis major muscle fascia, concomi-
tant en bloc excision of a portion of the directly underly-
ing pectoralis major muscle was generally performed. No
percentage criteria for the minimum required amount of
breast tissue that was necessary to be resected from theBMC Cancer 2009, 9:254 http://www.biomedcentral.com/1471-2407/9/254
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affected breast was used in this rationale for the extent of
the BCS procedure, but rather this rationale was based
upon the determination of the appropriateness of the
extent of resection, and when determined necessary, to
include all layers comprising the field of the affected
breast (i.e., skin, breast parenchyma, pectoralis major
muscle fascia, and pectoralis major muscle) in order to
maximize the likelihood of surgical resection margin
clearance. Each BCS specimen (Figure 1) was marked with
black silk sutures on the skin ellipse for specimen orienta-
tion. This generally consisted of a long black silk suture
marking the lateral edge of the skin ellipse and a short
black silk suture marking the superior edge of the skin
ellipse.
Once the BCS specimen was removed, rectangular-shaped
pieces of breast tissue were then systematically sampled
from nine standardized locations within the perimeter of
the resultant BCS resection bed cavity using curved Mayo
scissors and/or a #24 surgical blade (Figure 2). These rec-
tangular-shaped pieces of breast tissue were excised with
the curved Mayo scissors and/or a #24 surgical blade,
instead of with the coagulation mode of the electrocau-
tery, in order to generate no evidence of cautery artifact on
that particular surface of each sampled piece of breast tis-
sue. Therefore, in the end, the non-cauterized aspect of
each rectangular-shaped piece of breast tissue sampled
would represent the surface of the rectangular-shaped
piece of breast tissue that was furthest from the corre-
sponding resection margin of the originally submitted
BCS specimen that was removed from the affected breast
with the coagulation mode of the electrocautery and the
cauterized aspect of each rectangular-shaped piece of
breast tissue sampled would represent the surface of the
rectangular-shaped piece of breast tissue that was abutting
the corresponding resection margin of the originally sub-
mitted BCS specimen that was removed from the affected
breast with the coagulation mode of the electrocautery. In
this fashion, the distribution of electrocautery artifact on
each rectangular-shaped piece of breast tissue sampled
was used by the pathologist to help distinguish the actual
true margin surface (non-cauterized surface) from that of
the non-margin surface (cauterized surface) of each rec-
tangular-shaped piece of breast tissue sampled. These rec-
tangular-shaped pieces of breast tissue that where
systematically sampled from nine standardized locations
within the perimeter of the resultant BCS resection bed
cavity were designated as originating from the superior,
superior-medial, superior-lateral, medial, lateral, inferior,
inferior-medial, inferior-lateral, and deep-posterior
aspects of the resultant BCS resection bed cavity (Figures
2 and 3). These rectangular-shaped pieces of breast tissue
that were systematically sampled from nine standardized
locations within the perimeter of the resultant BCS resec-
tion bed cavity were designated as the nine standardized
re-resection margin specimens, as they are referred to
throughout the remainder of the current paper. Since the
anterior aspect of the BCS specimen was covered by an
overlying skin ellipse (in all but two cases), there was no
anterior re-resection margin designation for the resultant
BCS resection bed cavity.
Intraoperative sectioning and subsequent intraoperative
gross assessment of BCS margins on the BCS specimens
were not undertaken by the operating surgeon within the
operating room for any of the 204 BCS cases. This was
done in this fashion at the request of the Surgical Pathol-
ogy Department in order to maintain the integrity of the
intact BCS specimen for standard tissue processing that
would be subsequently performed in the Surgical Pathol-
ogy Department. However, in appropriately selected
cases, verification of the relationship of the tumor, mark-
ing clip, and/or biopsy cavity to the edges of the BCS spec-
imen was evaluated on non-compression specimen
mammography and/or on intraoperative specimen
sonography of the intact BCS specimen.
Both the BCS specimen and the nine standardized re-
resection margin specimens for each BCS case were sent to
the Surgical Pathology Department for standard tissue
processing. The three-dimensional measurements
(length, height, and width) of each submitted specimen
were recorded.
After standard tissue processing, each BCS specimen was
inked in a color-specific fashion using multiple colored
inks to designate the superior, medial, lateral, inferior,
deep-posterior, and anterior-skin surfaces. Each BCS spec-
imen was then grossly serially sectioned (at a thickness of
Photograph of a typical example of a breast-conserving sur- gery (BCS) specimen taken from a left breast Figure 1
Photograph of a typical example of a breast-conserv-
ing surgery (BCS) specimen taken from a left breast.BMC Cancer 2009, 9:254 http://www.biomedcentral.com/1471-2407/9/254
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approximately 5 mm for each serial section and in an
anterior skin surface to posterior direction) along the
entire long axis length of the BCS specimen (i.e., by a
standard perpendicular margins/radial margins tech-
nique). The macroscopic three-dimensional measure-
ments (length, height, and width) of the tumor, residual
tumor, or previous diagnostic excisional biopsy cavity
identified within each BCS specimen were recorded, as
well as the microscopic distance of the tumor, residual
tumor, or previous diagnostic excisional biopsy cavity
from the superior, medial, lateral, inferior, deep-posterior,
and anterior-skin inked surfaces of the BCS specimen.
Along the periphery of each BCS specimen, six standard-
ized locations were sampled as BCS specimen margins,
and were designated as the superior, medial, lateral, infe-
rior, deep-posterior, and anterior-skin margins of the BCS
specimen. All submitted BCS specimen tissue sections
were processed for permanent histopathologic evaluation
with routine Hematoxylin and Eosin (H&E) staining. No
intraoperative frozen section analysis was undertaken for
microscopic evaluation of the BCS specimen margins. The
six designated BCS specimen margin locations along the
periphery of each BCS specimen were microscopically
assessed at the time of permanent histopathologic evalua-
tion for the presence or absence of invasive carcinoma or
DCIS. The six designated BCS specimen margin locations
along the periphery of each BCS specimen were then each
defined as a "positive" BCS specimen margin, a "close"
BCS specimen margin, or a "negative" BCS specimen mar-
gin, based upon the finding of invasive carcinoma or
DCIS at the six designated BCS specimen margin loca-
tions. A "positive" BCS specimen margin was defined as
tumor cells seen at the inked edge of the BCS specimen
[3,8]. A "close" BCS specimen margin was defined as
tumor cells seen within 1 mm or less of the inked edge of
the BCS specimen, but no tumor cells seen at the inked
edge of the BCS specimen. A "negative" BCS specimen
margin was defined as no tumor cells seen within 1 mm
or less of the inked edge of the BCS specimen. For the six
designated BCS specimen margin locations along the
periphery of each BCS specimen, the exact distance to the
closest BCS specimen margin was determined. However,
for those individuals who had undergone a previous sur-
gical (excisional) biopsy as their initial diagnostic breast
biopsy and had no residual disease within the BCS speci-
men, the exact distance to the closest BCS specimen mar-
gin could not be determined. For all cases in which BCS
specimen margins were reported generically as "close"
(and not reported as an exact numerical measurement) in
the original official pathology report, repeat microscopic
histopathologic evaluation was subsequently performed
by a pathologist (REJ) to more precisely determine the
exact numerical measurement of the distance between
tumor and the inked edge of the BCS specimen. The pres-
ence of only LCIS, atypical lobular hyperplasia, or atypical
ductal hyperplasia within any one of the six designated
BCS specimen margin locations along the periphery of
each BCS specimen was not considered a "positive" find-
ing for margin definition purposes.
The nine standardized re-resection margin specimens col-
lected on each BCS case were inked with black ink, serially
sectioned, and submitted in entirety for processing for
permanent histopathologic evaluation with routine H&E
staining. No intraoperative frozen section analysis was
undertaken for intraoperative microscopic evaluation of
any of the nine standardized re-resection margin speci-
mens. All nine standardized re-resection margin speci-
mens were assessed for the presence ("positive") or
absence ("negative") of invasive carcinoma or DCIS. The
presence of only lobular carcinoma in situ, atypical lobu-
lar hyperplasia, or atypical ductal hyperplasia within a
standardized re-resection margin specimen was not con-
sidered a "positive" finding. The electrocautery artifact on
each of the nine standardized re-resection margin speci-
mens was specifically used by the pathologist to evaluate
the relationship any focus of invasive carcinoma or DCIS
within each standardized re-resection margin specimen to
that of its actual margin surface (non-cauterized surface)
and its non-margin surface (cauterized surface).
Computer-generated representation of the resultant breast- conserving surgery (BCS) resection bed cavity and the BCS  specimen resulting from a BCS procedure performed on a  left breast Figure 2
Computer-generated representation of the resultant 
breast-conserving surgery (BCS) resection bed cavity 
and the BCS specimen resulting from a BCS proce-
dure performed on a left breast. In this example, the 
area of the BCS resection bed cavity has been bisected along 
its long axis to illustrate the exact spatial location from 
where the nine standardized re-resection margins were sam-
pled from the superior (S), superior-medial (SM), superior-
lateral (SL), medial (M), lateral (L), inferior (I), inferior-medial 
(IM), inferior-lateral (IL), and deep-posterior (DP) aspects of 
the BCS resection bed cavity.
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The concordance and disconcordance of the spatial loca-
tion of a positive re-resection margin specimen in com-
parison to the margin status of the corresponding BCS
specimen was assessed for all cases in which there was at
least one positive re-resection margin among the nine
submitted standardized re-resection margin specimens.
When both a BCS specimen margin was defined as a "pos-
itive" margin or as a "close" margin and one or more of
the standardized re-resection margin specimens was
defined as "positive", the spatial location of these findings
were evaluated to assess concordance versus disconcord-
ance of these findings. A concordant finding was defined
as having an exact-matched finding within the same-
named location or a near-matched finding within the
same-named location for a BCS case having both a "posi-
tive" margin or a "close" margin on the BCS specimen at
a specifically defined margin location (i.e., superior,
medial, lateral, inferior, or deep-posterior) and a "posi-
tive" standardized re-resection margin specimen of the
corresponding standardized re-resection specimen loca-
tion (i.e., superior, superior-medial, superior-lateral,
medial, lateral, inferior, inferior-medial, inferior-lateral,
or deep-posterior). In this instance, an exact-matched
finding was defined as being within the same-named loca-
tion for the BCS specimen margin location (as pertaining
only to the superior, medial, lateral, inferior, and deep-
posterior aspects) and for the standardized re-resection
margin specimen location (as pertaining only to the supe-
rior, medial, lateral, inferior, and deep-posterior aspects).
In this instance, a near-matched finding was defined as
being within one adjacent location for the BCS specimen
margin location (as pertaining only to the superior,
medial, lateral, and inferior aspects) and for the standard-
ized re-resection margin specimen location (as pertaining
only to the superior, superior-medial, superior-lateral,
medial, lateral, inferior, inferior-medial, and inferior-lat-
eral aspects). A disconcordant finding was defined as hav-
ing a non-matched finding of a "positive" margin or a
"close" margin on the BCS specimen at a specifically
defined margin location as compared to the "positive"
standardized re-resection margin location. In this
instance, a non-matched finding was defined as being at a
spatial distance of more than one adjacent location away
from one another for the BCS specimen margin locations
(as pertaining only to the superior, medial, lateral, and
inferior aspects) and for the standardized re-resection
margin specimen locations (pertaining only to the supe-
rior, superior-medial, superior-lateral, medial, lateral,
inferior, inferior-medial, and inferior-lateral aspects).
Additionally, we utilized the term disconcordant finding
to define a BCS case in which there were "negative" BCS
margins while having one or more "positive" standard-
ized re-resection margin locations. Lastly, in those
instances in which there were multiple "positive" findings
for a given BCS case, the classification could be expanded
to include concordant findings, disconcordant findings,
or both simultaneously concordant and disconcordant
findings.
The histopathologic findings from the official, finalized
pathology report for each BCS case was discussed in per-
son with each patient at the one-week postoperative fol-
low-up visit. The potential clinical significance and
implications of any abnormal findings seen on his-
topathologic evaluation (i.e., concern of a compromised
surgical margin of resection as defined by a positive BCS
specimen margin, a close BCS specimen margin, and/or a
positive re-resection margin) were explained to each
patient. All scenarios, in which further surgical interven-
tion to the affected breast was thought to be of potential
benefit, were fully disclosed to and discussed with each
patient and those scenarios were appropriately managed
in those patients who accepted such further surgical inter-
vention to the affected breast.
Patients were referred to radiation oncology for consider-
ation of standard postoperative whole-breast radiation
therapy to the affected breast as part of their breast-con-
serving therapy. Additionally, patients were referred to
Photograph of a typical example of the nine standardized re- resection margins sampled from the superior (S), superior- medial (SM), superior-lateral (SL), medial (M), lateral (L), infe- rior (I), inferior-medial (IM, inferior-lateral (IL), and deep- posterior (DP) aspects of a left-sided breast-conserving sur- gery (BCS) resection bed cavity Figure 3
Photograph of a typical example of the nine stand-
ardized re-resection margins sampled from the supe-
rior (S), superior-medial (SM), superior-lateral (SL), 
medial (M), lateral (L), inferior (I), inferior-medial 
(IM), inferior-lateral (IL), and deep-posterior (DP) 
aspects of a left-sided breast-conserving surgery 
(BCS) resection bed cavity.BMC Cancer 2009, 9:254 http://www.biomedcentral.com/1471-2407/9/254
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medical oncology for consideration of postoperative adju-
vant therapy, when appropriate. All attempts were made
to maintain ongoing, serial patient follow-up with all
patients. However, some patients have remained non-
compliant and have not maintained ongoing, serial fol-
low-up, even after multiple attempts to arrange such
follow-up for these noncompliant patients.
The volume of each BCS specimen was calculated using
the formula of the volume of an ellipsoid [4/3·π·length
axis radius·width axis radius·height axis radius], rather
than using the formula of the volume of a cuboid
[length·width·height], since the three-dimensional
shape of any given BCS specimen generally better approx-
imated that of an ellipsoid rather than that of a cuboid.
The volume of the nine standardized re-resection margin
specimens was calculated using the formula of the volume
of a cuboid, rather than the formula of the volume of an
ellipsoid, since each standardized re-resection margin
specimen generally better approximated that of a cuboid
rather than that of an ellipsoid. The three-dimensional
surface area of each BCS specimen was calculated using
the derived formula of the surface area of an ellipsoid
[18,19]. Due to the significant complexity of the formula
used to calculate the surface area of an ellipsoid, the deri-
vation of that formula will not be shown within the text
of the current paper. The computer program MATLAB®
(The MathWorks, Inc., Natick, Massachusetts) was used to
assist in the calculation the surface area of an ellipsoid
from the three-dimensional measurements (length,
height, and width) of each BCS specimen. The two-
dimensional surface area of the face of each standardized
re-resection margin specimen, based on the two largest
dimensions of each standardized re-resection margin
specimen (i.e., length and width), was calculated simply
using the formula of the two-dimensional area of a rectan-
gle [length·width]. The following percentage were then
calculated: (1) the percentage of the cumulative volume of
all nine standardized re-resection margins as compared to
each BCS specimen volume, (2) the percentage of cumu-
lative 2-dimensional surface area of all nine standardized
re-resection margins as compared to the surface area of
each BCS specimen, and (3) the percentage of the cumu-
lative 2-dimensional surface area of all nine standardized
re-resection margins as compared to the surface area of
each BCS specimen minus the surface area of the overlying
skin ellipse.
For this study, data collection of all variables analyzed was
accomplished by way of retrospective review of the elec-
tronic medical records system of The Ohio State Univer-
sity Medical Center. Multiple variables were assessed and
evaluated, including patient demographics, tumor varia-
bles, specimen variables, and patient follow-up variables.
The software program SPSS® 16.0 for Windows® (SPSS,
Inc., Chicago, Illinois) was used for the data analyses of all
variables captured during data collection. For univariate
comparisons of categorical variables, either Pearson chi-
square test or Fisher exact test was utilized. For univariate
comparisons of continuous variables, one-way analysis of
variance (ANOVA) was utilized. All reported univariate P-
values were two-sided. All univariate P-values determined
to be 0.05 or less were considered to be significant. Multi-
variate logistic regression analysis was performed in
appropriately selected situations on all variables with a
univariate P-value of 0.10 or less, in order to assess for the
determination of possible independent predictors.
Results
From August 2003 to June 2007, 204 BCS procedures
were performed for invasive breast cancer by a single sur-
geon (SPP). Patient demographics and tumor characteris-
tics for all 204 BCS cases are shown in Table 1 and Table
2, respectively. Of the 204 BCS procedures, 164 were per-
formed as BCS procedures in patients with an intact
tumor who had undergone only a minimally-invasive
diagnostic breast biopsy at the time of initial diagnosis
and 40 were performed as re-excision BCS procedures in
patients who had previously undergone a surgical (exci-
sional) biopsy as their initial diagnostic breast biopsy.
Measurement variables for the BCS specimens are shown
in Table 3. Measurement variables for the nine standard-
ized re-resection margin specimens are shown in Table 4.
The percentage of the cumulative volume of all nine
standardized re-resection margins as compared to each
BCS specimen volume, the percentage of cumulative 2-
dimensional surface area of all nine standardized re-resec-
tion margins as compared to the surface area of each BCS
specimen, and the percentage of the cumulative 2-dimen-
sional surface area of all nine standardized re-resection
margins as compared to the surface area of each BCS spec-
imen minus the surface area of the overlying skin ellipse
are shown in Table 5.
A description of the margin status of the BCS specimen
and the re-resection margin status of the nine standard-
ized re-resection margin specimens at the time of the orig-
inal BCS procedure for all 204 BCS cases is shown in Table
6. Likewise, a description of the frequency of BCS cases
undergoing a subsequent re-excision breast procedure and
the frequency of BCS cases in which residual disease was
found within those subsequent re-excision breast proce-
dure specimens is shown in Table 6.
Among all 204 BCS cases, 13 (6.4%) had a positive BCS
specimen margin and 9 (4.4%) had a close BCS specimen
margin, thus giving a total of 22 (10.8%) cases having
either a positive or close BCS specimen margin (Table 6).
Of those 13 cases in which there was a positive BCS spec-
imen margin, eight had one positive BCS specimen mar-BMC Cancer 2009, 9:254 http://www.biomedcentral.com/1471-2407/9/254
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gin, three had two positive BCS specimen margins, and
two had three positive BCS specimen margins, thus repre-
senting 20 total positive BCS specimen margins among a
total of 1224 BCS specimen margin locations evaluated
for the 204 BCS cases. Of those 22 cases in which there
was a positive or close BCS specimen margin, 17 had one
positive/close BCS specimen margin, three had two posi-
tive/close BCS specimen margins, and two had three pos-
itive/close BCS specimen margins, thus representing 29
total positive/close BCS specimen margins among a total
of 1224 BCS specimen margin locations evaluated for the
204 BCS cases. A summary of the findings for all the pos-
itive BCS specimen margin cases and the positive or close
BCS specimen margin cases is shown in Table 7.
For the 164 patients that had an intact tumor at the time
of the BCS procedure, the mean microscopic distance of
tumor to the closest BCS specimen margin was 0.70 cm
(range, 0 to 2.00 cm). Additionally, for those 164 patients
that had an intact tumor at the time of the BCS procedure,
the mean microscopic distance of tumor to the closest
BCS specimen margin was 0.79 cm (range, 0.16 to 2.00
cm) for those classified as having a negative BCS specimen
margin (n = 146) as compared to 0.05 cm (range, 0.01 to
0.09) for those classified as having a close BCS specimen
margin (n = 7) (P < 0.001).
Among the 204 BCS cases, 24 had a positive re-resection
margin for one or more of the nine standardized re-resec-
tion margin specimens (Table 6). Of those 24 cases in
which there was a positive re-resection margin, 15 had
one positive re-resection margin, two had two positive re-
resection margins, five had three positive re-resection
margins, one had four positive re-resection margins, and
one had five positive re-resection margins, thus represent-
ing 43 total positive re-resection margins among a total of
1836 re-resection margin specimens for the 204 BCS
cases. A summary of the findings for all the positive re-
resection specimens is show in Table 8. All patients with
multiple positive re-resection margins accepted such fur-
ther surgical intervention to the affected breast, except for
one patient who refused further surgical intervention to
the affected breast, as well as refused consideration of any
other form of adjuvant therapy.
The concordance and disconcordance of the spatial loca-
tion of a positive re-resection margin specimen in com-
parison to the margin status of the BCS specimen was
assessed for all 24 cases in which there was at least one
positive re-resection margin (Table 9) and was assessed
for all 11 cases in which the BCS specimen had at least one
positive/close margin and there was also a positive re-
resection margin (Table 10). As is shown in Table 9, of the
24 cases that had at least one positive re-resection margin,
only 5 of 24 (20.8%) had completely concordant findings
with the margin status of the BCS specimen, while 15 of
24 (62.5%) had completely disconcordant findings and
19 of 24 (79.2%) had some degree of disconcordant find-
ings with the margin status of the BCS specimen. As is
shown in Table 10, of the 11 patients that had at least one
positive/close margin and at least one positive re-resec-
tion margin, only 5 of 11 (45.5%) had completely con-
cordant findings between the positive/close BCS
specimen margin status and the positive re-resection mar-
gin status, while 2 of 11 (18.2%) had completely discon-
cordant findings and 6 of 11 (54.5%) had some degree of
disconcordant findings between the positive/close BCS
specimen margin status and the positive re-resection mar-
gin status.
As shown in Table 11, any potential association of the
patient demographic variables and tumor characteristic
variables from Table 1 and Table 2 with a "positive final
margin status" was assessed by both univariate and multi-
variate analyses. For the purpose of these analyses, we
broadly defined a "positive final margin status" as having
either a positive BCS specimen margin, a close BCS speci-
men margin, or an involved (positive) re-resection margin
specimen. On univariate analysis, associated DCIS (P =
0.032) and larger tumor size (P = 0.034) were associated
with a positive final margin status, whereas invasive lobu-
lar carcinoma displayed only a nonsignificant trend (P =
0.095). On multivariate analysis, associated DCIS (P =
0.015) and invasive lobular carcinoma (P = 0.052) were
associated with a positive final margin status, whereas
larger tumor size displayed only a nonsignificant trend (P
= 0.066). Thus, associated DCIS was the only variable
associated with a "positive final margin status" by both
univariate and multivariate analyses.
A description of the frequency of cases undergoing a sub-
sequent re-excision breast procedure and the frequency of
cases in which residual disease was found within those
subsequent re-excision breast procedure specimens is also
shown in Table 6. Of those 13 cases in which there was a
positive BCS specimen margin, 7 (53.8%) elected to
undergo a further re-resection breast procedure, including
five undergoing a re-excision BCS procedure, one under-
going a completion mastectomy, and one undergoing a
re-excision BCS procedure (with further positive margins)
followed by a completion mastectomy. Of those 22 cases
in which there was a positive or close BCS specimen mar-
gin, 11 (50.0%) elected to undergo a further re-excision
breast procedure, including six undergoing a re-excision
BCS procedure, four undergoing a completion mastec-
tomy, and one undergoing a re-excision BCS procedure
(with further positive margins) followed by a completion
mastectomy. Of those 35 cases in which there was a posi-
tive BCS specimen margin, a close BCS specimen margin,
or a positive re-resection margin specimen, 16 (45.7%)BMC Cancer 2009, 9:254 http://www.biomedcentral.com/1471-2407/9/254
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elected to undergo a further re-excision breast procedure,
including seven undergoing a re-excision BCS procedure,
eight undergoing a completion mastectomy, and one
undergoing a re-excision BCS procedure (with further pos-
itive margins) followed by a completion mastectomy.
Of the 204 BCS cases, 174 patients have maintained serial
follow-up (with a mean follow-up duration of 38.6
months and a range of follow-up duration from 19.1 to
63.4 months), 22 patients have been noncompliant and
have not maintained any identifiable follow-up, and eight
patients are currently known to be deceased. Only three
documented recurrences of disease related to their breast
cancer are known within this series. This includes: (1) a
case of recurrence within multiple distant sites in an indi-
vidual undergoing a BCS procedure with an intact tumor
(with positive BCS margins) who declined initial evalua-
tion of the axillary lymph nodes, declined a subsequent
recommended re-excision BCS procedure or completion
mastectomy, and declined other recommended adjuvant
therapies (with recurrence 4 months after the original BCS
procedure); (2) a case of concurrent recurrence within the
completion mastectomy site and multiple distant sites in
an individual undergoing a re-excision BCS procedure
(with positive BCS margins) and evaluation of the axillary
lymph nodes and a subsequent completion mastectomy
(with recurrence 7.5 and 6.5 months, respectively, after
the original re-excision BCS procedure and subsequent
completion mastectomy); and (3) a case of concurrent
recurrence within the re-excision BCS site and multiple
osseous metastases in an individual undergoing a re-exci-
sion BCS procedure (with negative BCS margins) and
evaluation of the axillary lymph nodes (with recurrence
15 months after the original re-excision BCS procedure).
No isolated local recurrences within the treated breast
alone have been identified. Of the eight known deaths
identified during the study period, two deaths are from
among the three cases of documented recurrent breast
cancer described above, five deaths are secondary to pro-
gression of other concurrent malignancies (including lung
cancer in two cases, colon cancer in one case, lymphoma
in one case, and leukemia in one case), and one death is
from other (i.e. non-oncologic) causes.
Discussion
The determination of the adequacy of BCS has long been
debated among clinicians involved in the management of
invasive breast cancer [8-17]. Central to this ongoing
debate has been the definition of "adequate" or "nega-
tive" surgical resection margins, as well as the determina-
Table 1: Patient demographics of all 204 BCS cases
Patient demographics Number (percentage or range)
Age (years) 57 (27 – 87)
Height (inches) 65 (54 – 72)
Weight (pounds) 175 (96 – 342)
Body mass index 29.6 (16.6 – 58.7)
Race
Caucasian 175 (86%)
Black 29 (14%)
Menopausal status
Postmenopausal 154 (76%)
Premenopausal 43 (21%)
Perimenopausal 7 (3%)
Breast sidedness
Right 98 (48%)
Left 106 (52%)
Breast size
Small (approximately A-cup) 17 (8%)
Medium (approximately B-cup) 82 (40%)
Large (approximately C-cup) 76 (37%)
Extra-large (approximately D-cup or greater) 29 (14%)
Neoadjuvant therapy 30 (14.7%)
Neoadjuvant systemic chemotherapy 24 (11.8%)
Neoadjuvant anti-estrogen therapy 6 (2.9%)
BCS, breast-conserving surgeryBMC Cancer 2009, 9:254 http://www.biomedcentral.com/1471-2407/9/254
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tion of what is the most optimal manner in which to
assess the adequacy of the surgical resection margins. As
illustrated in Table 12, the definition and determination
of margin positivity during BCS for invasive breast cancer
varies widely among all reported series [20-68]. From the
endless number of discussions and commentaries on this
topic within the medical literature [8-17], it is quite clear
that there is absolutely no consensus among clinicians in
regards to these important questions. And quite frankly, it
is doubtful that any generalized consensus will ever be
reached in the near future. Nevertheless, developing a
standardized and reproducible methodology for the com-
Table 2: Tumor characteristics of all 204 BCS cases
Tumor characteristics Number (percentage or range)
Originally palpable mass
Yes 79 (39%)
No 112 (55%)
Indeterminate 13 (6%)
Tumor (pT) size (centimeters) 1.6 (0.08 – 6.0)
Tumor location
Upper outer quadrant 105 (52%)
Upper inner quadrant 40 (20%)
Lower outer quadrant 29 (14%)
Lower inner quadrant 22 (11%)
Subareolar 8 (4%)
Tumor histopathology
Invasive ductal carcinoma 165 (81%)
Invasive lobular carcinoma 12 (6%)
Mixed invasive ductal and lobular carcinoma 8 (4%)
Invasive carcinoma not otherwise specified 7 (3%)
Mucinous (colloid) carcinoma 7 (3%)
Papillary carcinoma 3 (2%)
Adenoid cystic carcinoma 2 (1%)
Histologic grade
Well-differentiated 52 (25%)
Moderately-differentiated 71 (35%)
Poorly-differentiated 81 (40%)
Estrogen receptor positive 155 (76%)
Progesterone receptor positive 135 (66%)
Her 2 Neu positive 26 (12.7%)
Lymphovascular invasion 36 (18%)
Associated ductal carcinoma in situ (DCIS) 131 (64%)
Associated axillary lymph node involvement
Yes 37 (18%)
No 158 (78%)
Not assessed 9 (4%)
Type of original diagnostic breast biopsy
14-gauge core biopsy 74 (36%)
8- or 11-gauge ultrasound mammotome biopsy 52 (25%)
8- or 11-gauge stereotactic mammotome biopsy 38 (19%)
Surgical (excisional) biopsy 40 (20%)
BCS, breast-conserving surgeryBMC Cancer 2009, 9:254 http://www.biomedcentral.com/1471-2407/9/254
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prehensive and systematic assessment of surgical resection
margins during BCS for invasive breast cancer while still
limiting the volume of additional breast tissue excised
remains an important issue to clinicians for most opti-
mally assessing which individuals need further resection
of the affected breast and for minimizing the long-term
risks of local recurrence following BCS.
In our current series, 6.4% (13/204) of patients had posi-
tive BCS specimen margins (defined as tumor cells at the
inked edge of the BCS specimen) and 4.4% (9/204) of
patients had close margins (defined as tumor cells within
1 mm or less of the inked edge but not at the inked edge
of the BCS specimen). Based on a 1 mm or less criteria for
the concern of a compromised surgical margin of resec-
tion at the time of a BCS procedure, a total of 10.8% (22/
204) of patients were counseled about the potential clini-
cal significance and implications of these findings. Our
results, as compared to the multitude of other reported
series showed in Table 12[20-68], are very respectable and
are reflective of both the adherence to appropriate patient
selection for BCS that was used by the surgeon performing
these BCS procedures as well as the standardized rationale
and technique that was used by the surgeon for the deter-
mination of the extent of tissue resection during each BCS
procedure. Additionally, 11.8% (n = 24) of all 204
patients had at least one re-resection margin containing
additional invasive carcinoma or DCIS, independent of
the status of the BCS specimen margins. This included
7.1% (n = 13) of the 182 patients with negative BCS spec-
imen margins (defined as no tumor cells seen within 1
mm or less of the inked edge of the BCS specimen) who
had at least one re-resection margin containing additional
invasive carcinoma or DCIS. Therefore, of the total of 24
patients with at least one re-resection margin containing
additional invasive carcinoma or DCIS, 13 (54.2%, P <
0.001) represented individuals that had additional adja-
cent invasive carcinoma or DCIS that was not recognized
by a standard BCS procedure alone, based upon the find-
ings of negative BCS specimen margins (Table 9). Of a
similarly related note regarding disconcordance, even
when one or more of the BCS specimen margins were pos-
itive/close, 6 of 11 (54.5%) of such patients that also had
at least one positive re-resection margin had some degree
of disconcordance between the positive/close BCS speci-
men margin status and the positive re-resection margin
status (Table 10), thus further recognizing the failure of
surgical resection margin assessment that is solely based
upon only evaluating the BCS specimen margins them-
selves.
The pattern of having disconcordant findings, in which
there are negative margins on the BCS specimen itself
despite the finding of further disease within additionally
re-excised tissue from within the BCS resection bed cavity,
has been previously reported by multiple other authors
[22,30,38,43,47,53,66,68]. In 1994, England et al [22]
reported finding positive disease in the "tumour bed
biopsy" re-excision specimens in 9.6% (5/52) of patients
with initial negative "wide local excision" margins. In
1998, Beck et al [30] reported finding positive disease in
the "entire cavity wall" re-excision specimen in 13.3%
(14/105) of patients with initial negative "wide local exci-
sion" margins. In 2001, Jenkinson et al [38] reported find-
ing positive disease in the "cavity bed biopsy" re-excision
specimens in 6.0% (5/83) of patients with initial negative
"segmental mastectomy" margins. In 2004, Keskek et al
[43] reported finding positive disease in "complete cavity
margin excision" specimens in 4.3% (13/303) of patients
with initial negative margins on the "initial tumour exci-
sion". In 2005, Cao et al [47] reported finding positive
disease in the "cavity margin" re-excision specimens in
8.7% (2/23) of patients with initial negative "lumpec-
tomy" margins. In 2006, Huston et al [53] reported find-
ing positive disease in "additional margin" specimens in
6.4% (3/26) of patients with initial negative "lumpec-
tomy" margins. In 2009, Tengher-Barna et al [66] reported
finding positive disease in "cavity margin" specimens in
10.3% (11/107) of patients with initial negative "lumpec-
tomy" margins. Finally, in 2009, Hewes et al [68] reported
Table 3: Summary of BCS specimen variables from the pathology report of the 204 BCS cases
BCS specimen variables Mean measurement (range)
Dimension 1: Length (cm) 8.5 (4.4 – 18.7)
Dimension 2: Width (cm) 6.8 (2.5 – 12.8)
Dimension 3: Height (cm) 3.1 (2.0 – 7.0)
Volume of BCS specimen (cm3) 103.3 (12.0 – 538.9)
Surface area of BCS specimen (cm2) 122.5 (28.9 – 437.9)
Surface area of overlying skin ellipse (cm2) 8.0 (0 – 47.1)
Surface area of BCS specimen minus overlying skin ellipse (cm2) 113.7 (21.2 – 421.7)
Weight (gm) 86.9 (15 – 330)#
BCS, breast-conserving surgery
#: The BCS specimen weight was available for only 162 of the 204 BCS cases.BMC Cancer 2009, 9:254 http://www.biomedcentral.com/1471-2407/9/254
Page 11 of 23
(page number not for citation purposes)
Table 4: Summary of the nine standardized re-resection margin variables from the pathology report of the 204 BCS cases
Re-resection margin variables Mean measurement (range)
Superior (S) re-resection margin
Volume (cm3) 2.74 (0.17 – 19.24)
2-dimensional surface area (cm2) 4.23 (0.56 – 23.20)
Superior-Medial (SM) re-resection margin
Volume (cm3) 2.60 (0.04 – 50.11)
2-dimensional surface area (cm2) 3.77 (0.20 – 28.50)
Superior-Lateral (SL) re-resection margin
Volume (cm3) 2.44 (0.14 – 52.73)
2-dimensional surface area (cm2) 3.85 (0.50 – 28.40)
Medial (M) re-resection margin
Volume (cm3) 3.09 (0.05 – 36.00)
2-dimensional surface area (cm2) 4.50 (0.20 – 36.00)
Lateral (L) re-resection margin
Volume (cm3) 2.69 (0.16 – 15.12)
2-dimensional surface area (cm2) 4.12 (0.80 – 21.60)
Inferior (I) re-resection margin
Volume (cm3) 3.04 (0.10 – 24.57)
2-dimensional surface area (cm2) 4.66 (0.50 – 18.90)
Inferior-Medial (IM) re-resection margin
Volume (cm3) 2.33 (0.10 – 31.50)
2-dimensional surface area (cm2) 3.80 (0.30 – 15.80)
Inferior-Lateral (IL) re-resection margin
Volume (cm3) 2.33 (0.10 – 10.10)
2-dimensional surface area (cm2) 4.05 (0.50 – 20.30)
Deep-Posterior (DP) re-resection margin
Volume (cm3) 3.29 (0.10 – 66.00)
2-dimensional surface area (cm2) 4.67 (0.10 – 33.00)
Cumulative volume (cm3) of all nine standardized re-resection margins 24.55 (2.20 – 135–57)
Cumulative 2-dimensional surface area (cm2) of all nine standardized re-resection margins 37.66 (6.19 – 102.66)
BCS, breast-conserving surgery
Table 5: Summary of percentage of cumulative volume of all nine standardized re-resection margins as compared to the BCS 
specimen volume, percentage of cumulative 2-dimensional surface area of all nine standardized re-resection margins as compared to 
the surface area of the BCS specimen, and percentage of cumulative 2-dimensional surface area of all nine standardized re-resection 
margins as compared to the surface area of the BCS specimen minus the surface area of the overlying skin ellipse from the pathology 
report of the 204 BCS cases
Variables Percentage (range)
Percentage of cumulative volume of all nine standardized re-resection margins as compared to the BCS specimen volume 26.8% (3.5% – 85.7%)
Percentage of cumulative 2-dimensional surface area of all nine standardized re-resection margins as compared to the 
surface area of the BCS specimen
32.6% (7.5% – 96.3%)
Percentage of cumulative 2-dimensional surface area of all nine standardized re-resection margins as compared to the 
surface area of the BCS specimen
minus the surface area of the overlying skin ellipse 34.9% (8.1% – 98.2%)
BCS, breast-conserving surgeryBMC Cancer 2009, 9:254 http://www.biomedcentral.com/1471-2407/9/254
Page 12 of 23
(page number not for citation purposes)
finding positive disease in "cavity biopsy" specimens in
8.6% (82/957) of patients with initial negative "wide
local excision" margins.
In this specific regard, the disconcordance of having neg-
ative BCS specimen margins and positive re-resection
margins (Table 9), as well as the high degree of discon-
cordance shown in cases having both positive/close BCS
specimen margins and positive resection margins (Table
10), appears to signify that a substantial percentage of
failed BCS procedures may result, not necessarily from
unrecognized positive or close margins on the BCS speci-
men itself, but rather from the presence of adjacent multi-
focal disease within the same quadrant of the affected
breast upon which the BCS procedure was performed.
Beck et al [30] described this phenomenon as a "discon-
tinuous growth pattern commonly seen around primary
tumours". Other investigators examining BCS have also
described this phenomenon [69,70]. Likewise, Holland et
al [71] previously evaluate and discussed this phenome-
non in a retrospective review of mastectomy specimens
from 1980 to 1982 in which 121 of 282 (43%) mastec-
tomy specimens from patients that would have theoreti-
cally been candidates for BCS based on standard clinical
and radiographic criteria for that time period had addi-
tional disease within the affected breast that was greater
than 2 cm from the known breast cancer. Despite the
plausibility of our above explanation, which is clearly
Table 6: Description of the margin status of the BCS specimen and the re-resection margin status of the nine standardized re-
resection margin specimens at the time of the original BCS procedure for all 204 BCS cases, as well as the description of the frequency 
of patients undergoing a subsequent re-excision breast procedure and the frequency of finding residual disease within those 
subsequent re-excision breast procedure specimens
Description of margin variables for 
original BCS procedure
Status of margin variables for 
original BCS specimen
Frequency of a subsequent re-
excision
Frequency of residual disease
Positive BCS specimen margin(s) 13/204 (6.4%) 7/13 (53.8%)#,£ 2/7 (28.6%)
Close BCS specimen margin(s) 9/204 (4.4%) 4/9 (44.4%)¶ 2/4 (50.0%)
Positive or close BCS specimen margin(s) 22/204 (10.8%) 11/22 (50.0%)Ω ,£ 4/11 (36.4%)
Negative BCS specimen margins 182/204 (89.2%) 0/182 (0%) not applicable
Positive re-resection margin(s) 24/204 (11.8%) 15/24 (62.5%)* ,±, Ø,  4/15 (26.7%)
Positive BCS specimen margin(s) AND 
positive re-resection margin(s)
8/204 (3.9%) 7/8 (87.5%)£ 2/7 (28.6%)
Close BCS specimen margin(s) AND 
positive re-resection margin(s)
3/204 (1.5%) 3/3 (100%) 1/3 (33.3%)
Positive or close BCS specimen margin(s) 
AND positive re-resection margin(s)
11/204 (5.4) 10/11 (90.9%)£ 3/10 (30.0%)
Positive BCS specimen margin(s) AND 
negative re-resection margins
5/204 (2.5%) 0/5 (0%)# not applicable
Close BCS specimen margin(s) AND 
negative re-resection margins
6/204 (2.9%) 1/6 (16.7%)¶ 1/1 (100%)
Positive or close BCS specimen margin(s) 
AND negative re-resection margins
11/204 (5.4%) 1/11 (9.1%)Ω 1/1 (100%)
Negative BCS specimen margins AND 
positive re-resection margin(s)
13/204 (6.4%)@ 5/13 (38.5%)* ,± 0/5 (0%)
Negative BCS specimen margins AND 
negative re-resection margins
169/204 (82.8%) 0/169 (0%) not applicable
Positive BCS specimen margin(s) AND/
OR close BCS specimen margin(s) AND/
OR positive re-resection margin(s)
35/204 (17.2%) 16/35 (45.7%)Ω, *, ±, Ø 5/16 (31.3%)
BCS, breast-conserving surgery
#: Five patients with a positive BCS specimen margin declined a subsequent re-excision procedure due to the finding of nine negative standardized 
re-resection margins.
¶: Five patients with a close BCS specimen margin declined a subsequent re-excision procedure due to the finding of nine negative standardized re-
resection margins.
£: One patient refused the recommendation of the surgeon for the absolute need of a subsequent re-excision procedure.
Ω: Ten patients with a positive or close BCS specimen margin declined a subsequent re-excision procedure due to the finding of nine negative 
standardized re-resection margins.
*: Five patients declined a subsequent re-excision procedure due to the finding of one isolated positive standardized re-resection margin out of nine 
standardized re-resection margins in which the noncauterized surface (i.e., actual true margin surface) of that standardized re-resection margin was 
free of tumor and therefore was considered a microscopically negative final margin.
±: Three patients refused the recommendation of the surgeon for the absolute need of a subsequent re-excision procedure.
Ø: One patient declined a subsequent re-excision procedure due to the finding of in situ carcinoma within one standardized re-resection margin for 
which it could not be distinguished as to whether it represented lobular carcinoma in situ versus ductal carcinoma in situ.
: Eight of nine patients with multiple positive standardized re-resection margins agreed to a subsequent re-excision procedure.
@: 7.1% (13/182) of patients with negative BCS specimen margins had at least one re-resection margin containing additional tumor.BMC Cancer 2009, 9:254 http://www.biomedcentral.com/1471-2407/9/254
Page 13 of 23
(page number not for citation purposes)
supported by the work of other investigators [30,69-71],
that adjacent multifocal disease within the same quadrant
of the affected breast may contribute to the occurrence of
many failed BCS procedures, we can not rule out that
some failed BCS procedures may result from suboptimal
surgical resection margin assessment techniques that fail
to recognized positive or close margins on the BCS speci-
men itself. Nevertheless, in regards to the issue of the
potential presence of adjacent multifocal disease within
the same quadrant of the affected breast upon which the
BCS procedure is being performed, obtaining nine stand-
ardized re-resection margin specimens, as proposed in our
current study, allows one to systematically and methodi-
cally assess the adjacent breast tissue for multifocality
within the same quadrant of the affected breast and may
allow one to select out those individuals who would be
better suited for completion mastectomy who had addi-
tional multifocal disease within the same quadrant that
would have otherwise been unrecognized by traditional
resectional techniques for BCS that did not routinely uti-
lize some sort of re-resection margin technique.
This line of reasoning does not disagree with the well-held
contention that most breast cancers recurrences within the
breast after BCS occur within the same quadrant of the
affected breast and not within a different quadrant of the
affected breast [30,70,72-76]. Instead, our line of reason-
ing agrees with this well-held contention since it is our
belief that such recurrences within the affected breast rep-
resent a failure of BCS, in the sense that there is a failure
to recognize adjacent multifocality located adjacent to the
primary tumor mass rather than a failure of the traditional
Table 7: Summary of the total number of individual instances in which any one of the designated BCS specimen margin sites was 
positive or was positive/close from the pathology report of the 204 BCS cases
BCS specimen margin Number of instances in which there was a positive BCS 
specimen margin
Histopathology of each positive BCS specimen 
margin
Superior (S) margin 3 2 IDC, 1 ACC
Medial (M) margin 5 2 IDC, 2 ILC, 1 DCIS
Lateral (L) margin 3 1 IDC, 1 ILC, 1 DCIS
Inferior (I) margin 5 2 IDC, 2 ILC, 1 DCIS
Deep-Posterior (DP) margin 4 2 IDC, 1 ILC, 1 ACC
Anterior-Skin (AS) margin 0 not applicable
BCS specimen margin Number of instances in which there was a positive/close 
BCS specimen margin
Histopathology of each positive/close BCS specimen 
margin
Superior (S) margin 3 2 IDC, 1 ACC
Medial (M) margin 8 5 IDC, 2 ILC, 1 DCIS
Lateral (L) margin 4 2 IDC, 1 ILC, 1 DCIS
Inferior (I) margin 6 2 IDC, 2 ILC, 2 DCIS
Deep-Posterior (DP) margin 8 4 IDC, 1 ILC, 2 DCIS, 1 ACC
Anterior-Skin (AS) margin 0 not applicable
BCS, breast-conserving surgery; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; DCIS ductal carcinoma in situ; ACC, adenoid cystic 
carcinoma
Table 8: Summary of the total number of individual instances in which any one of the designated nine standardized re-resection 
margin sites was positive for disease from the pathology report of the 204 BCS cases
Re-resection margin Number of instances in which there was a positive 
re-resections margin
Histopathology of each positive re-resection 
margin
Superior (S) re-resection margin 5 2 IDC, 2 DCIS, 1 ACC
Superior-Medial (SM) re-resection margin 4 1 IDC, 2 DCIS, 1 ACC
Superior-Lateral (SL) re-resection margin 4 1 IDC, 1 ILC, 2 DCIS
Medial (M) re-resection margin 5 3 IDC, 2 DCIS
Lateral (L) re-resection margin 5 3 IDC, 2 DCIS
Inferior (I) re-resection margin 7 2 IDC, 5 DCIS
Inferior-Medial (IM) re-resection margin 3 2 IDC, 1 DCIS
Inferior-Lateral (IL) re-resection margin 7 3 IDC, 4 DCIS
Deep-Posterior (DP) re-resection margin 3 2 DCIS, 1 ACC
BCS, breast-conserving surgery; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; DCIS ductal carcinoma in situ; ACC, adenoid cystic 
carcinomaBMC Cancer 2009, 9:254 http://www.biomedcentral.com/1471-2407/9/254
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resectional technique itself to remove the primary tumor
mass in its entirety from the affected breast. Thus, by using
the nine standardized re-resection margin technique to
identify as many such cases that are not realistically
amendable to BCS and that instead are truly in need of a
completion mastectomy to successfully remove all multi-
focality of the breast cancer, it is possible that such an
approach could ultimately translate into less local breast
recurrences from successful BCS procedures (i.e., better
patient selection for those who can be successfully man-
aged by BCS and better patient selection for those who
should be best managed by completion mastectomy).
Multiple authors have previously described various meth-
odologies for attempting to recognize residual disease
within the walls of the BCS resection bed cavity of the
affected breast that is not otherwise well appreciated by
the current generally accepted technique of only evaluat-
ing of the margins of the BCS specimen alone [21-
23,27,29-32,34,38,43,47,48,53,54,61,66,68,77,78]. Spe-
cific to this discussion are those studies that have focus
specifically upon methods of further removal of tissue
from the walls of the BCS resection bed cavity after the
removal of the BCS specimen. Some of those authors have
described a "selective cavity margin sampling" technique
[21,22,29,31,32,38,47,48,53,54,61,66,68,77,78], while
others have described "complete cavity margin re-exci-
sion" technique [23,27,30,34,43]. Such a discussion will
not include those studies specifically addressing method-
ologies for image-guided wire placement, intraoperative
ultrasound guidance, radioguided techniques for guiding
the resection of the BCS specimen, or intraoperative detec-
tion of electrical property changes or optical property
changes within the BCS resection bed cavity.
As is shown in Table 13, those authors that have described
a "selective cavity margin sampling" technique show great
variability in their sampling methodology
[21,22,29,31,32,38,47,48,53,54,61,66,68,77,78]. These
various methods of "selective cavity margin sampling"
[21,22,29,31,32,38,47,48,53,54,61,66,68,77,78] were all
very effective at demonstrating additional disease within
the affected breast that would have been otherwise unrec-
ognized by the current generally accepted technique of
evaluation of the margin status of the BCS specimen
alone. Additionally, a collective conclusion drawn by each
of these studies that specifically evaluated the overall BCS
margin status based upon both the "selective cavity mar-
gin sampling" specimens and the BCS specimen itself was
that such a combined approach also effectively reduced
the need for a subsequent re-excision procedure to the
affected breast at a later time as compared to the reliance
only upon the current generally accepted technique of
evaluation of the margin status of the BCS specimen
alone, specifically for those individuals with involved BCS
specimen margins but uninvolved "selective cavity margin
sampling" specimens [47,53,61,66,68]. In contrast to the
various "selective cavity margin sampling" techniques
shown in Table 13 which generally sample up to six areas
within the BCS resection bed cavity
[21,22,29,31,32,38,47,48,53,54,61,66,68,77,78], our
technique of nine standardized re-resection margins
attempts to further maximize the number of surfaces of
the BCS resection bed cavity that are sampled and evalu-
ated, while still limiting the total amount of additional
breast tissue removed.
Several authors have described a technique of "complete
cavity margin re-excision" for comprehensive evaluation
Table 9: Concordance or disconcordance of the spatial location of a positive re-resection margin specimen in comparison to the 
margin status of the corresponding spatial location on each BCS specimen for each of the 24 cases in which there as at least one 
positive re-resection margin specimen
Description of margin variables and concordance/disconcordance Frequency
Negative BCS specimen margins AND positive re-resection margins (disconcordant findings) 13/24 (54.2%)
Positive/close BCS specimen margins AND positive re-resection margins (concordant findings) 5/24 (20.8%)
Positive/close BCS specimen margins AND positive re-resection margins (disconcordant findings) 2/24 (8.3%)
Positive/close BCS specimen margins AND positive re-resection margins (both concordant and disconcordant findings) 4/24 (16.7%)
BCS, breast-conserving surgery
Table 10: Concordance or disconcordance of the spatial location of a positive re-resection margin specimen in comparison to the 
margin status of the corresponding spatial location on each of the 11 cases in which the BCS specimen had at least one positive/close 
margin and there was also a positive re-resection margin
Description of margin variables and concordance/disconcordance Frequency
Positive/close BCS specimen margins AND positive re-resection margins (concordant findings) 5/11 (45.5%)
Positive/close BCS specimen margins AND positive re-resection margins (disconcordant findings) 2/11 (18.2%)
Positive/close BCS specimen margins AND positive re-resection margins (both concordant and disconcordant findings) 4/11 (36.4%)
BCS, breast-conserving surgeryBMC Cancer 2009, 9:254 http://www.biomedcentral.com/1471-2407/9/254
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of the surgical resection margins at the time of BCS
[23,27,30,34,43]. Although the "complete cavity margin
re-excision" technique seems ideal for achieving the most
thorough assessment of the surgical resection margins, it
significantly increases the overall volume of tissue
removed from the affected breast, it is limited by breast
size, and it frequently leads to very suboptimal cosmetic
results. MacMillan and colleagues [23,27,24] described a
method of "complete cavity margin re-excision" in which
the entire cavity wall was excised as a single continuous
shell of tissue that was evaluated by permanent histopa-
thology, but for which no data was reported on the mar-
gin status of the BCS specimen. Beck et al [30] described a
method of "complete cavity margin re-excision" in which
the entire cavity wall was excised as a single continuous
ring of tissue that was evaluated by permanent histopa-
thology along with evaluation of the margins of the BCS
specimen. Keskek et al [43] described a method of "com-
plete cavity margin re-excision" in which the entire cavity
wall was excised as four separate specimens (designated
superior, lateral, inferior, and medial) that were evaluated
by permanent histopathology along with evaluation of
the margins of the BCS specimen. These various methods
of "complete cavity margin re-excision" [23,27,30,34,43]
were all very effective at demonstrating additional disease
within the affected breast that would have been otherwise
unrecognized by the current generally accepted technique
of evaluation of the margin status of the BCS specimen
alone. However, the major drawback to the "complete
cavity margin re-excision" technique is that the amount of
tissue removed by performing the "complete cavity mar-
gin re-excision" can essentially equal the amount of tissue
removed as the BCS specimen itself [30], thus doubling
the total size the BCS resection bed cavity within the
affected breast and thus subsequent negatively impacting
on the cosmetic outcome of the BCS procedure. In con-
trast to the "complete cavity margin re-excision" tech-
niques [23,27,30,34,43], our technique of nine
standardized re-resection margins minimizes amount of
additional tissue excised from the affected breast for accu-
rate assessment of the presence or absence of further dis-
ease around the BCS specimen (i.e., representing only
26.8% of the volume of the BCS specimen and 32.6% of
the surface area of the BCS specimen) while still maximiz-
ing the number of different surfaces within the BCS resec-
tion bed cavity that are sampled (i.e., nine standardized
re-resection margins).
Several investigators have addressed and debated the effi-
cacy of the technique of performing gross intraoperative
examination of the BCS margins and selective immediate
intraoperative re-excision of any given BCS margin that is
thought to represent a suspicious or compromised margin
[45,46,56,63] as a mechanism to reduce the need for a
subsequent second re-excision procedure. We did not uti-
lize this methodology in our series of 204 BCS procedures.
Table 11: Potential association of patient and tumor variables with a positive final margin status (i.e., as defined as either having a 
positive margin, a close margin, or a positive re-resection margin) as determined by univariate and multivariate analyses
Patient and tumor variables Univariate P-value Multivariate P-value
Age 0.601 NA
Height 0.469 NA
Weight 0.977 NA
Body mass index 0.799 NA
Race 0.792 NA
Menopausal status 0.777 NA
Breast sidedness 0.296 NA
Breast size 0.771 NA
Neoadjuvant therapy 0.655 NA
Originally palpable mass 0.647 NA
Tumor size 0.034 0.066
Tumor location 0.411 NA
Tumor histopathology (invasive lobular carcinoma) 0.095 0.052
Histologic grade 0.727 NA
Estrogen receptor positive 0.541 NA
Progesterone receptor positive 0.132 NA
Her 2 Neu positive 0.473 NA
Lymphovascular invasion 0.374 NA
Associated DCIS 0.032 0.015
Associated axillary lymph node involvement 0.182 NA
Type of original diagnostic breast biopsy 0.430 NA
DCIS, ductal carcinoma in situBMC Cancer 2009, 9:254 http://www.biomedcentral.com/1471-2407/9/254
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Table 12: Studies reporting margin positivity with breast-conserving surgery (BCS)*,#
Citation Positive margin status (results and definition)
McCormick 1987 [20] 24.1% (26/108), defined as tumor at edge
Umpleby 1988 [21] 25.0% (13/52), defined as tumor in cavity bed specimens and not based on BCS specimen
England 1994 [22] 35.0% (28/80), defined as tumor < 1 mm from edge
MacMillan 1994 [23] 38.3% (101/264), defined as tumor in cavity bed specimens and not based on BCS specimen
Schnitt 1994 [24] 47.5% (86/181), defined as tumor at edge; 61.3% (111/181), defined as tumor ≤ 1 mm from edge
Beron 1996 [25] 51.9% (41/79), defined as tumor < 1 mm from edge
Gage 1996 [26] 38.5% (131/340), defined as tumor at edge, 54.4% (185/340), defined as tumor ≤ 1 mm from edge
MacMillan 1997 [27] 39.3% (118/300), defined as tumor in cavity bed specimens and not based on BCS specimen
Saarela 1997 [28] 14.5% (8/55), defined as tumor at edge
Weber 1997 [29] 15.0% (21/140), defined as tumor in cavity bed specimens and not based on BCS specimen
Beck 1998 [30] 27.1% (39/141), defined as tumor at edge
DiBiase 1998 [31] 19.0% (86/453), defined as tumor in cavity bed specimens and not based on BCS specimen
Taylor 1998 [32] 25.4% (68/268), defined as tumor in cavity bed specimens and not based on BCS specimen
Horiguchi 1999 [33] 22.4% (36/161), defined as tumor < 5 mm from edge
Malik 1999 [34] 36.8% (200/543), defined as tumor in cavity bed specimens and not based on BCS specimen
Papa 1999 [35] 29.1% (115/395), defined as tumor at edge
Park 2000 [36] 36.0% (192/533), defined as tumor at edge; 53.7% (286/533), defined as tumor ≤ 1 mm from edge
Gibson 2001 [37] 44.5% (243/546), defined as tumor at edge
Jenkinson 2001 [38] 18.8% (19/101), defined as tumor at edge
Moore 2001 [39] 15.7% (8/51), defined as tumor at edge
Swanson 2002 [40] 32.7% (85/260), defined as tumor at edge; 45.0% (117/260), defined as tumor < 2 mm from edge
Mai 2003 [41] 25.8% (16/62), defined as tumor < 1 mm from edge
Chagpur 2004 [42] 12.4% (329/2658), defined as tumor at edge
Keskek 2004 [43] 39.6% (120/303), defined as tumor ≤ 2 mm from edge
Miller 2004 [44] 18.4% (26/141), defined as tumor at edge
Fleming 2004 [45] 9.1% (20/220), defined as tumor < 5 mm from edge
Balch 2005 [46] 25.1% (64/255), defined as tumor < 2 mm from edge
Cao 2005 [47] 81.7% (103/126), defined as tumor ≤ 2 mm from edge
Cendán 2005 [48] 44.3% (43/97), defined as tumor in cavity bed specimens and not based on BCS specimen
Dooley 2005 [49] 11.4% (25/220), defined as tumor ≤ 1 mm from edge
Nadeem 2005 [50] 30.0% (39/130), defined a tumor < 1 mm from edge
Aziz 2006 [51] 14.3% (205/1430), defined as tumor at edge
Dillon 2006 [52] 34.5% (211/612), defined as tumor < 5 mm from edge
Huston 2006 [53] 61.4% (105/171), defined as tumor < 2 mm from edge
Janes 2006 [54] 44.2% (96/217), defined as tumor < 5 mm from edge
Méndez 2006 [55] 64.6% (115/178), defined as tumor ≤ 2 mm from edge
Cabioglu 2007 [56] 13.6% (27/200), defined as tumor at edge; 32.7% (65/200), defined as tumor ≤ 2 mm from edge
Kotwall 2007 [57] 52.6% (306/582), defined as tumor at edge
Smitt 2007 [58] 43.5% (172/395), defined as tumor at edge
Wright 2007 [59] 16.0% (42/263), defined as tumor at edge; 41.8% (110/263), defined as tumor ≤ 1 mm from edge
Dillon 2008 [60] 19.9% (56/281), defined as tumor < 2 mm from edge; 32.0% (90/281), defined as tumor < 5 mm from edge
Jacobson 2008 [61] 66.4% (83/125), defined as tumor ≤ 2 mm from edge
Schiller 2008 [62] 17.0% (124/730), defined as tumor at edge; 34.9% (255/730), defined as tumor < 1 mm from edge
Soucy 2008 [63] 18.4% (88/478), defined as tumor at edge
Lovrics 2008 [64] 19.6% (65/332), defined as tumor at edge
Sabel 2009 [65] 18.2% (173/948), defined as tumor at edge; 32.0% (303/948), defined as tumor ≤ 2 mm from edge
Tengher-Barna 2009 [66] 43.9% (47/107), defined as tumor ≤ 3 mm from edge
Munhoz 2009 [67] 28.8% (63/218), no definition of margin positivity given
Hewes 2009 [68] 20.5% (196/957), defined a tumor < 1 mm from edge
Povoski 2009 6.4% (13/204), defined as tumor at edge, 10.8% (22/204), defined as tumor ≤ 1 mm from edge
BCS, breast-conserving surgery
* This table excludes any previous studies that included in their analyses a significant percentage of patients with an "unknown" or "indeterminate" 
margin status in comparison to the reported percentage of patients with a positive margin status since this "unknown" or "indeterminate" variable 
would not allow for an accurate determination of the percentage of patients with margin positivity.
# Some of these previous studies not only included individual undergoing a definitive BCS procedure, but also individuals undergoing only a 
diagnostic surgical excisional breast biopsy. In many such cases, this subtle distinction was not well articulated and likely accounted for their 
relatively high reported margin positivity rates.BMC Cancer 2009, 9:254 http://www.biomedcentral.com/1471-2407/9/254
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As with any proposed technique, no universal consensus
has been reach on the efficacy of performing gross intra-
operative examination of the BCS margins and selective
immediate intraoperative re-excision of BCS margins that
are thought to represent suspicious or compromised mar-
gins. Although this assessment technique for surgical
resection margins varies to some degree between reported
series, it is primarily based upon the gross visual inspec-
tion of the intact BCS specimen as well as gross visual
inspection the cut surface of inked, non-fixed, sectioned
BCS specimen at the time of BCS. In this regard, it is quite
evident that one faction strongly favors its use [45] while
another faction does not [46].
Fleming et al [45] have previously reported that "intraop-
erative macroscopic margin assessment" is an effective
technique for reducing the number of second operations
in patients undergoing BCS for primary invasive breast
cancer. They demonstrated that only 9.1% (20/220) of
patients required a second operation when "intraopera-
tive macroscopic margin assessment" was utilized as com-
pared to 21.4% (47/220) of patients would have required
a second operation if "intraoperative macroscopic margin
assessment" had not been utilized. However, interest-
ingly, in their study, only 19.8% (16/81) of patients that
had macroscopically suspicious or compromised margins
(as they defined as suspected tumor grossly/macroscopi-
cally within 10 mm of any given gross/macroscopic mar-
gin) at the time of the initial BCS surgery in which they
then performed further selective immediate intraoperative
re-excision of BCS margins actually had a final histologic-
confirmed positive margin status on the original BCS
specimen (as they defined as invasive carcinoma or DCIS
at a distance of less than 5 mm from the microscopic mar-
gin on permanent histopathology). In such series as Flem-
ing et al [45], as well as others [33,45,52,54,79,80] that
routinely advocate very wide microscopic margins of at
least 5 mm on permanent histopathology to define a mar-
gin status as negative, the utilization of our proposed nine
standardized re-resection margins technique for the BCS
resection bed cavity would have allowed those surgeon to
consider far less extreme criteria for a negative margin sta-
tus on the BCS specimen itself and may have provided
them with more confidence that complete tumor excision
had been successfully accomplished.
In contract, Balch et al [46] have previously reported that
"intraoperative gross examination" of surgical resection
margins was not particularly useful for patients undergo-
ing BCS for breast cancer. In their study, they reported that
only 32.6% (46/141) of patients that had grossly suspi-
cious or compromised margins (as they defined as sus-
pected tumor grossly/macroscopically within 5 mm of
any given gross/macroscopic margin) at the time of the
initial BCS actually had final histologically positive mar-
gins on the original BCS specimen (as they defined as
invasive carcinoma or DCIS at a distance of within 2 mm
from the microscopic margin on permanent histopathol-
ogy). Additionally, they reported that "intraoperative
gross examination" of surgical resection margins did not
accurately reflect the margin status since 28.1% (18/64) of
patients with final histologically positive margins (as they
defined as invasive carcinoma or DCIS at a distance of
within 2 mm from the microscopic margin on permanent
histopathology) were initially thought to have grossly
tumor-free margins (as they defined as no suspected
tumor grossly/macroscopically within 5 mm of any given
gross/macroscopic margin). Therefore, they recom-
mended consideration of other potential techniques for
intraoperative evaluation of surgical resection margins to
attempt to reduce the need for a subsequent re-excision in
patients undergoing BCS.
For the assessment of surgical resection margins on the
BCS specimen itself, it is pertinent for us to discuss and
contrast the use of the "tangential shaved margins" tech-
nique [9,55,59,81] versus that of the currently more
widely accepted "perpendicular margins" technique (i.e.,
"radial margins" technique). In our series, the assessment
of the surgical resection margins on the BCS specimen
itself was performed by obtaining perpendicular sections
along the entire long axis length of the BCS specimen,
thus recognizably representing a rather limited sampling
of the total margin surface of the BCS specimen. With the
"perpendicular margins" technique on the BCS specimen
itself, it is only when tumor cells are present at the inked
edge of a particular perpendicular section being micro-
scopically examined that the surgical resection margin is
considered positive. The major advantage of this "perpen-
dicular margins" method is that the relationship and accu-
rate measurement of the distance between the tumor and
the surgical resection margin surface of the BCS specimen
itself can be microscopically evaluated. Alternatively, sur-
gical resection margins on the BCS specimen can be
assessed by utilizing the so called "tangential shaved mar-
gins" technique [9,55,59,81]. In this method, the surface
of the BCS specimen itself is either shaved [55,59,81] or
peeled [9], and the resulting thin tissue sections are placed
flat in cassettes for embedding, resulting in tangentially
sectioned surfaces for microscopic margin assessment.
With the "tangential shaved margins" technique, the pres-
ence of any tumor cells within an examined section is
grounds for interpretation as a positive surgical resection
margin status. Because one is actually tangential section-
ing into the periphery of the BCS specimen itself with the
use of the "tangential shaved margins" technique, a meas-
urement of the actual distance between the tumor and the
surgical resection margin surface of the BCS specimen
itself can not be accurately determined. Nevertheless,
major advantage of this "tangential shaved margins" tech-BMC Cancer 2009, 9:254 http://www.biomedcentral.com/1471-2407/9/254
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nique is that the total area of the general periphery of the
BCS specimen itself that is microscopically examined is
significantly greater. Therefore, the use of one or the other
of these two sampling techniques, when applied to the
BCS specimen itself, represent a compromise between
allowing direct microscopic visualization of the relation-
ship between the tumor and the surgical resection mar-
gins and providing variable degrees of the total breast
tissue "surface" area that is microscopically examined for
surgical margin assessment.
It is evident that the use of the "tangential shaved mar-
gins" technique on the BCS specimen itself [59] results in
a significantly higher rate of "margin positivity" than what
is generally seen by the more widely accepted technique of
"perpendicular margins" for assessment of surgical resec-
tion margins on the BCS specimen itself. Since, within our
current study methodology, we did not compare the effi-
cacy of the "tangential shaved margins" technique versus
that of the "perpendicular margins" technique for assess-
ment of surgical resection margins on the BCS specimen
itself, it is difficult for us to critically debate the pros and
cons of the use of the "tangential shaved margins" tech-
nique for assessment of surgical resection margins on the
BCS specimen itself. Nevertheless, we, as well as others
[59,81,82], do recognize that, in general, the concept of a
"tangential shaved margins" technique is an obvious and
important step toward improving the currently accepted
and utilized methodology for the assessment of surgical
resection margins on the BCS specimen alone. This is sim-
ply because the "tangential shaved margins" technique on
the BCS specimen itself dramatically increases the total
breast tissue "surface" area of the BCS specimen that is
available for surgical resection margin assessment, while,
on the other hand, the "perpendicular margins" technique
on the BCS specimen itself can be intrinsically less sensi-
tive secondary to the fact that it provides surgical resection
margin assessment of only a much smaller fraction of the
surface area of the BCS specimen itself. Yet, at the same
time, we also believe that the use of the "tangential shaved
Table 13: Studies reporting "selective cavity margin sampling" techniques for breast-conserving surgery (BCS)
Citation Methodology for "selective cavity margin sampling"
Umpleby 1988 [21] 5 "cavity biopsies" from the superior, inferior, lateral, medial, and deep margins of the cavity wall that were evaluated 
by permanent histopathology, but for which no data was reported on the margin status of the BCS specimen
England 1994 [22] 5 "tumour bed biopsies" from the superior, inferior, medial, lateral, and base of cavity that were evaluated by 
permanent histopathology along with evaluation of the margins of the BCS specimen
Weber 1997 [29] 5 "tumor cavity biopsies" from the medial, lateral, superior, inferior, and deep aspects of the lumpectomy cavity that 
were evaluated by frozen section and permanent histopathology, but for which no data was reported on the margin 
status of the BCS specimen
Dibiase 1998 [31] 5 "tumor cavity shaved biopsies" from the medial, lateral, superior, inferior, and base of cavity that were evaluated by 
permanent histopathology, but for which no data was reported on the margin status of the BCS specimen
Taylor 1998 [32] 4 "bed biopsies" from each of the 4 quadrants of the post-resection bed that were evaluated by permanent 
histopathology, but for which no data was reported on the margin status of the BCS specimen
Jenkinson 2001 [38] 4 "tumour bed biopsies" from each of the 4 quadrants of the post-resection bed that were evaluated by permanent 
histopathology along with evaluation of the margins of the BCS specimen
Cao 2005 [47] 4 to 6 "cavity margins" from either the superior, inferior, medial, lateral, anterior, and/or posterior aspects of the 
residual cavity that were evaluated by permanent histopathology along with evaluation of the margins of the BCS 
specimen
Cendán 2005 [48] 5 to 6 "cavity margins" from either the lateral, medial, inferior, superior, deep, and/or superficial aspects of the 
lumpectomy cavity that were evaluated by frozen section and permanent histopathology, but for which no data was 
reported on the margin status of the BCS specimen
Huston 2006 [53] Comparative study of taking 4 to 6 "additional margins" versus 1 to 3 "additional margins" versus no "additional 
margins" (with the specific excision locations not designated for those "additional margins") that were evaluated by 
permanent histopathology along with evaluation of the margins of the BCS specimen
Janes 2006 [54] 2 standardized "cavity shaves" from the superior and inferior aspects of the residual cavity that were evaluated by 
permanent histopathology along with evaluation of the margins of the BCS specimen
Olson 2007 [77] 3 to 6 "cavity margin biopsies" from the walls of the BCS cavity that were evaluated by frozen section and permanent 
histopathology, but for which no data was reported on the margin status of the BCS specimen
Jacobson 2008 [61] 4 to 6 "shaved margins" from either the superior, inferior, medial, lateral, anterior, and/or posterior aspect of the 
lumpectomy cavity that were evaluated by permanent histopathology along with evaluation of the margins of the BCS 
specimen
Marudanayagam 2008 [78] Up to 4 "cavity shavings" from either the superior, inferior, medial, and/or lateral aspects of the cavity that were 
evaluated by permanent histopathology, but for which no data was reported on the margin status of the BCS specimen
Tengher-Barna 2009 [66] 4 "cavity margins" from the lateral, medial, superior, and inferior of the lumpectomy cavity that were evaluated by 
permanent histopathology along with evaluation of the margins of the BCS specimen
Hewes 2009[68] 4 "cavity biopsies" from the 4 quadrants of the residual cavity that were evaluated by permanent histopathology along 
with evaluation of the margins of the BCS specimen
BCS, breast-conserving surgeryBMC Cancer 2009, 9:254 http://www.biomedcentral.com/1471-2407/9/254
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margins" technique on the BCS specimen itself is not nec-
essarily a true reflection of what is going on directly at the
surface of the BCS specimen itself, since it represent the
action of sectioning directly into the peripheral tissues of
the BCS specimen, a process which compromises the
integrity of the periphery of the BCS specimen and is
potentially fraught with many technical issues [82]. In our
estimation, a "selective cavity margin sampling" tech-
nique for the BCS resection bed cavity, which essential
represents an equivalent to the "tangential shaved mar-
gins" technique on the BCS specimen itself and which
allows for a greater percentage of the surface area of breast
tissue directly adjacent to the periphery of the BCS speci-
men itself (i.e., the BCS resection bed cavity) to be availa-
ble for surgical resection margin assessment (but without
compromising the integrity of the BCS specimen itself) is
a better solution. Therefore, as is the basis of our current
paper, when our nine standardized re-resection margin
technique is used as the "selective cavity margin sam-
pling" technique for the BCS resection bed cavity and is
combined with the generally accepted "perpendicular
margins" technique for assessment of surgical resection
margins on the BCS specimen itself, we believe that we
can achieved the "best of both worlds" with regards to the
development of a standardized and reproducible method-
ology for the comprehensive and systematic assessment of
surgical resection margins during BCS. Such a combined
approach gives rise to the concept of optimizing the deter-
mination of region clearance of tumor burden within the
affected breast by taking into account both the potential
for microscopically recognized or unrecognized compro-
mise of the surgical resection margins of the BCS speci-
men itself, as well as the potential for unrecognized
multifocality of disease within the same quadrant of the
affected breast.
Multiple authors [16,47,49,68,83] have previously dis-
cussed the technical issues related to the generation of
false positive margins on BCS specimens. General hand-
ing of the BCS specimen (that can take place either before
or after normal specimen processing and inking that
occurs in the pathology department), as well as specimen
compression at the time of specimen mammography, can
significantly impact upon the creation of artificially close
or false positive margins. Due to the friable and lobular
nature of the surfaces of both the fibrofatty tissue compo-
nent and mammary tissue component comprising the
freshly excised BCS specimen, any compression to the
freshly excised BCS specimen can create artificial crevices,
tissue thinning, and reorientation of the overlying fibro-
fatty tissue and mammary tissue covering the actual tumor
surface. This can result in decreasing the actual distance
between the surface of the freshly excised BCS specimen
and the surface of the tumor, as well as result in a change
in the orientation of which surface of the freshly excised
BCS specimen actually represents the true, closest margin.
The subsequent application of ink to the friable and lob-
ular surfaces of the freshly excised BCS specimen, and as
accentuated by the previous above described effect of
specimen compression, can result in the ingress of ink
into these artificial crevices and potential spaces located in
between the uneven, friable, and lobular surfaces of the
freshly excised BCS specimen that ultimately allows for
tracking and deposition of ink into locations more closely
approximating the surface of the tumor than are actually
representative of the true distance from the intended mar-
gin surface of the freshly excised BCS specimen to the
actual tumor surface. Additionally, the utilization of over-
generous amounts of ink, as well as the addition of any
excess force during the process of ink application to the
freshly excised BCS specimen and during the process of
removal of excess ink (i.e., "blotting dry") from the freshly
excised BCS specimen can further accentuate the ingress of
ink into potential spaces that are not representative of the
intended margin surface of the freshly excised BCS speci-
men. Taken together, all these above describe variables
may lead to the generation of artificially elevated false
positive margin rates and may be a major contributing fac-
tor in the alarmingly high rate of margin positivity
reported in many of the studies shown in Table 12[20-
68]. Better education of those individuals that are directly
involved in specimen transport, specimen mammo-
graphic evaluation, and specimen processing within the
pathology department may help to reduce these poten-
tially preventable causes of an artificially elevated rate of
margin positivity on BCS specimens.
When one reflects on the overall alarmingly high rate of
margin positivity reported by many previous series in the
literature and which is clearly illustrated within Table
12[20-68], the validity of such data that is thought to rep-
resent homogenous populations of patients undergoing
definitive BCS then comes into question. Clearly, some of
these previous reported series not only included individ-
ual undergoing a definitive BCS procedure, but also indi-
viduals undergoing only a diagnostic surgical excisional
breast biopsy. This subtle distinction was generally not
well articulated by the authors of such papers, and this
factor, in many cases, may have accounted for their rela-
tively high reported margin positivity rates. Two recent
studies have clearly addressed this issue [58,64]. Lovrics et
al [64] nicely illustrated the significance of having a con-
firmed preoperative diagnosis of invasive breast cancer on
margin positivity with BCS. They showed that 19.6% (65/
332) of patients had positive margins (defined by tumor
at cut edge) on BCS specimens when there was a con-
firmed preoperative diagnosis of invasive breast cancer
while 26.0% (127/489) of patients had positive margins
on BCS specimens when they included those patients
without a confirmed preoperative diagnosis of invasiveBMC Cancer 2009, 9:254 http://www.biomedcentral.com/1471-2407/9/254
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breast cancer. This translated into 42.2% (62/147) of
patients had positive margins on BCS specimens when
there was specifically no confirmed preoperative diagno-
sis of invasive breast cancer. This difference was highly sig-
nificant on both univariate and multivariate analyses (P <
0.001). Similarly, Smitt et al [58] showed that 71.3%
(234/328) of those without a preoperative diagnosis of
invasive breast cancer had positive/close margins (defined
by tumor within 2 mm from the inked edge) on the BCS
specimen in comparison to only 47.8% (32/67) of those
with a preoperative diagnosis of invasive breast cancer on
core/FNA had positive/close margins on the BCS speci-
men (P < 0.0001).
Finally, in our current series, the finding of DCIS in con-
junction with invasive carcinoma was the only variable
that we evaluated that was associated with a "positive final
margin status" on both univariate and multivariate analy-
ses (Table 11). This association of having a "positive final
margin status" when DCIS is found in conjunction with
invasive carcinoma has been previously described in the
literature [41,44,84]. Such an association is thought to be
an important predictor of finding residual disease within
the affected breast at the time of re-excision [25,85-87], as
well as an important predictor of long-term recurrence of
disease within the affected breast [88-96]. However, a
more in-depth characterization of this association can not
be gleaned from our current results since we did not
attempt to distinguish the simple finding of associated
DCIS from that of the more intricate definition of finding
of an extensive intraductal component associated with an
invasive breast cancer.
Conclusion
In our current report, we have presented a standardized
and reproducible methodology for comprehensive and
systematic assessment of surgical resection margins dur-
ing BCS. Such a combined approach gives rise to the con-
cept of determination of region clearance of tumor
burden within the affected breast by taking into account
both the potential for microscopically recognized or
unrecognized compromise of the surgical resection mar-
gins of the BCS specimen itself, as well as the potential for
unrecognized multifocality of disease within the same
quadrant of the affected breast. Our methodology accu-
rately assesses the adequacy of surgical resection margins
for determination of which individuals may need further
resection to the affected breast in order to minimize the
potential risk of local recurrence following BCS, while
attempting to limit the volume of additional breast tissue
excised at the time of BCS. Likewise, our methodology is
useful in determining which individuals are not realisti-
cally amendable to BCS and that are instead in need of a
completion mastectomy to successfully remove multifo-
cal disease that would have otherwise been unrecognized
by traditional resectional techniques for BCS that do not
routinely utilize some sort of re-resection margin tech-
nique.
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